Episode
PPP 180 - GLP-1 Agonist Update
- Podcast
- Purple Pen Podcast
- Published
- Nov 15, 2025
- Duration seconds
- 2995
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/purple-pen-podcast-53605/episodes/ppp-180-glp-1-agonist-update/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/purple-pen-podcast-53605/ppp-180-glp-1-agonist-update.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Listen in as Kristin chats with Dr Angela Kwong, a Sydney-based General Practitioner with a special interest in medically supervised weight management, about the use of GLP-1 agonists. Dr Kwong serves as the NSW State Lead for the RACGP Specific Interests Group in Obesity Management and works closely with colleagues across disciplines to improve care for people living with obesity. She is also the founder of Enlighten Me , a multidisciplinary online program that provides evidence-based, GP-led support for patients seeking weight management. The program has been recognised for its contribution to patient education and its focus on accessible, stigma-free care. Additional GLP-1 reading: 1. GLP-1 agonist role in renal protection - FLOW Trial 1a. Digestible summary of the FLOW trial 2. Current ANZCA guidelines for anaesthesia / sedation in patients using GLP-1 agonists (May 2025) 3. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity